LifeMD Announces CFO Transition and Expanded Leadership Team

LifeMD ( (LFMD) ) has shared an announcement.

On March 16, 2026, LifeMD announced that Chief Financial Officer Marc Benathen would leave the company to pursue a new opportunity, remaining through March 31, 2026, and then serving in a paid transition advisory role for up to a year, while forfeiting unvested restricted stock units and retaining those already vested. The company emphasized that his departure was not due to any disagreement over operations or policies and will cover his COBRA costs for up to a year, underscoring an orderly transition designed to stabilize finance leadership.

LifeMD simultaneously appointed veteran healthcare finance executive Atul Kavthekar as CFO effective March 16, 2026, granting him a $500,000 base salary, eligibility for a performance bonus, and 675,000 restricted stock units split between time-based and performance-based vesting to align his incentives with long-term value creation. His nearly three decades of experience across healthcare, pharmacy, e-commerce, and technology, along with his focus on capital markets, M&A and AI-driven operating leverage, position LifeMD to strengthen its financial infrastructure as it pursues an AI-first strategy and continued growth.

The company also expanded its leadership bench by promoting former CMO Jessica Friedeman to the newly created role of Chief Business Officer, where she will lead enterprise and employer health offerings while continuing to oversee the women’s health division. In addition, LifeMD named marketing veteran Chris Pisano as Chief Marketing Officer to drive brand strategy, digital marketing, and cross-selling initiatives intended to deepen patient relationships, increase lifetime value, and reinforce the company’s competitive standing in virtual care.

The most recent analyst rating on (LFMD) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on LifeMD stock, see the LFMD Stock Forecast page.

Spark’s Take on LFMD Stock

According to Spark, TipRanks’ AI Analyst, LFMD is a Neutral.

The score is held back primarily by uneven financial quality (2025 revenue decline, still-negative operating profitability, and volatile/free-cash-flow step-down), despite strong gross margins and a healthier balance sheet. Technicals are supportive in the intermediate term (price above key shorter moving averages and positive MACD), valuation appears reasonable on P/E, and earnings-call guidance/initiatives are constructive but tempered by competitive and margin/revision risks.

To see Spark’s full report on LFMD stock, click here.

More about LifeMD

LifeMD, Inc. is a U.S.-based telehealth company and leading provider of virtual primary care, offering telemedicine visits, access to laboratory and pharmacy services, and specialized treatment for more than 200 conditions, including primary care, men’s and women’s health, weight management, and hormone therapy. The company operates a vertically integrated digital care platform supported by a nationwide affiliated medical group, an affiliated pharmacy, and a U.S.-based patient care center to expand access to affordable, high-quality care.

Average Trading Volume: 1,237,621

Technical Sentiment Signal: Sell

Current Market Cap: $213M

See more insights into LFMD stock on TipRanks’ Stock Analysis page.